Atazanavir/cobicistat
Atazanavir/cobicistat (trade name Evotaz) is a fixed-dose combination antiretroviral medication used to treat and prevent HIV/AIDS. It contains atazanavir and cobicistat.[1] Atazanavir is an HIV protease inhibitor and cobicistat blocks the body's metabolism of atazanavir by the enzyme CYP3A prolonging its effectiveness.
| Combination of | |
|---|---|
| Atazanavir | HIV protease inhibitor |
| Cobicistat | Cytochrome P450 (CYP3A) inhibitor |
| Clinical data | |
| Trade names | Evotaz |
| ATC code | |
| Identifiers | |
| KEGG | |
It was approved by the Food and Drug Administration for use in United States in 2015.[2]
References
- "Evotaz Packing Insert" (PDF).
- "U.S. Food and Drug Administration Approves Bristol-Myers Squibb's Evotaz (atazanavir and cobicistat) for the Treatment of HIV-1 Infection in Adults" (Press release). Bristol-Myers Squibb.
External links
- "Atazanavir mixture with cobicistat". Drug Information Portal. U.S. National Library of Medicine.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.